introduction: autosomal dominant polycystic kidney disease (adpkd) is one of the most common genetic kidney disorders with the incidence of 1 in 1,000 births. adpkd is genetically heterogeneous with two genes identified: pkd1 (16p13.3, 46 exons) and pkd2 (4q21, 15 exons). eighty five percent of the patients with adpkd have at least one mutation in the pkd1 gene. genetic studies have demonstrate...

autosomal dominant polycystic kidney disease (adpkd) is an inherited disorder associated with multiple cyst formation in the different organs. development of pancreatic cyst in adpkd is often asymptomatic and is associated with no complication. a 38‑year‑old man with adpkd was presented with six episodes of acute pancreatitis and two episodes of cholangitis in a period of 12 months. various ima...

A combination of drugs reduces the growth cysts related to autosomal dominant polycystic kidney disease.

a. We recommend screening for polycystic liver disease in all patients diagnosed with autosomal dominant polycystic kidney disease using abdominal ultrasound (1C). b. We recommend that all female patients with autosomal dominant polycystic kidney disease and liver cysts undergo counseling regarding the risks of pregnancy and exogenous estrogen exposure in worsening liver cyst growth (1C). c. We...

Polycystic kidney disease is a multisystemic familial inherited disease. A symptomatic treatment approach the standard modality for autosomal dominant polycystic (ADPKD) complications and life-long 50% chronic renal failure risk, as transplantation only definitive treatment.

autosomal dominant polycystic kidney disease (adpkd) is the most common genetic nephropathy, which is characterized by replacement of renal parenchyma with multiple cysts. in iran, the disease prevalence within the chronic hemodialysis patient population is approximately 8-10%. so far, three genetic loci have been identified to be responsible for adpkd. little information is available concernin...

Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. Volume progression in autoso-mal dominant polycystic kidney disease: the major factor determining clinical outcomes. Magnetic resonan...

BACKGROUND AND OBJECTIVES Plasma copeptin, a marker of arginine vasopressin, is elevated in patients with autosomal dominant polycystic kidney disease and predicts disease progression. It is unknown whether elevated copeptin levels result from decreased kidney clearance or as compensation for impaired concentrating capacity. Data from patients with autosomal dominant polycystic kidney disease a...